These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24655741)

  • 1. New versus traditional approaches to oral anticoagulation in patients with atrial fibrillation.
    Reiffel JA
    Am J Med; 2014 Apr; 127(4):e15. PubMed ID: 24655741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFib treatment: general population.
    Rothman SA
    Am J Med; 2014 Apr; 127(4):e16. PubMed ID: 24655743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AFib in special populations.
    French WJ
    Am J Med; 2014 Apr; 127(4):e17-8. PubMed ID: 24655745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation and stroke: epidemiology.
    Reiffel JA
    Am J Med; 2014 Apr; 127(4):e15-6. PubMed ID: 24655742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral anticoagulants.
    Reiffel JA
    Am J Med; 2014 Apr; 127(4):e16-7. PubMed ID: 24655744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
    Lu Y; Branstad R; Karim RM; Asinger RW
    J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation.
    Lang NN; Connelly DT
    J R Coll Physicians Edinb; 2013; 43(2):151-8. PubMed ID: 23734359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations.
    Rosenberg DJ; Ansell J
    Hosp Pract (1995); 2012 Aug; 40(3):50-7. PubMed ID: 23086094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
    Hankey GJ
    Thromb Haemost; 2014 May; 111(5):808-16. PubMed ID: 24285341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices.
    Cairns JA
    Can J Cardiol; 2013 Oct; 29(10):1165-72. PubMed ID: 23932012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA
    Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.